9636 related articles for article (PubMed ID: 19903860)
1. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
2. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
3. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
4. [Topical pimecrolimus and tacrolimus and the risk of cancer].
Sánchez-Pérez J
Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
7. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
Ingram JR; Martin JA; Finlay AY
Am J Clin Dermatol; 2009; 10(4):229-37. PubMed ID: 19489656
[TBL] [Abstract][Full Text] [Related]
8. Off-label topical calcineurin inhibitor use in children.
Manthripragada AD; Pinheiro SP; MaCurdy TE; Saneinejad S; Worrall CM; Kelman JA; Graham DJ
Pediatrics; 2013 Nov; 132(5):e1327-32. PubMed ID: 24127469
[TBL] [Abstract][Full Text] [Related]
9. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Thaçi D; Salgo R
Clin Dermatol; 2010; 28(1):52-6. PubMed ID: 20082951
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
11. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema.
Meurer M; Lubbe J; Kapp A; Schneider D
Dermatology; 2007; 215 Suppl 1():18-26. PubMed ID: 18174690
[TBL] [Abstract][Full Text] [Related]
12. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
14. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
[TBL] [Abstract][Full Text] [Related]
15. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.
Wooltorton E
CMAJ; 2005 Apr; 172(9):1179-80. PubMed ID: 15817641
[No Abstract] [Full Text] [Related]
16. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Goldstein AT; Thaçi D; Luger T
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
18. Association Between Malignancy and Topical Use of Pimecrolimus.
Margolis DJ; Abuabara K; Hoffstad OJ; Wan J; Raimondo D; Bilker WB
JAMA Dermatol; 2015 Jun; 151(6):594-9. PubMed ID: 25692459
[TBL] [Abstract][Full Text] [Related]
19. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
[TBL] [Abstract][Full Text] [Related]
20. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals.
Djalilian HR; Memar O
Laryngoscope; 2006 Oct; 116(10):1809-12. PubMed ID: 17003726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
